Evidence map›Paper›PMID 41421982›Full record

ArticleBMC infectious diseases2025

Serological evidence of concurrent Lassa virus and SARS-CoV-2 exposure in Ghana- a cross-sectional study.

Elizabeth Obeng-Aboagye, Angelica Daakyire, Portia Owusua Aniapam, Amanda Lamptey, Grace Opoku Gyamfi, Emmanuel Frimpong Gyekye, Christopher Dorcoo, Elvis Suatey Lomotey, Irene Owusu Donkor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabeth Obeng-AboagyeDepartment of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box LG 581, Legon, Accra, Ghana.
Angelica DaakyireDepartment of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O.Box LG 581, Legon, Accra, Ghana.
Portia Owusua AniapamDepartment of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O.Box LG 581, Legon, Accra, Ghana.
Amanda LampteyDepartment of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O.Box LG 581, Legon, Accra, Ghana.
Grace Opoku GyamfiDepartment of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O.Box LG 581, Legon, Accra, Ghana.
Emmanuel Frimpong GyekyeDepartment of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box LG 581, Legon, Accra, Ghana.
Christopher DorcooDepartment of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O.Box LG 581, Legon, Accra, Ghana.
Elvis Suatey LomoteyDepartment of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O.Box LG 581, Legon, Accra, Ghana.
Irene Owusu DonkorDepartment of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box LG 581, Legon, Accra, Ghana. iowusu@noguchi.ug.edu.gh.

Funding

African Academy of Sciences SARS-CoV2-4-004Bill and Melinda Gates Foundation INV ID - 024130WHO AFRO 2021/1166179-0
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has exposed vulnerabilities in infectious disease surveillance, especially in West Africa where endemic viruses including Lassa fever persist. The overlapping clinical symptoms of these two infections create diagnostic challenges and the possibility of undetected co-infections.

methodsA retrospective cross-sectional study was conducted using archived serum samples from a nationwide SARS-CoV-2 seroprevalence survey in Ghana. 434 samples across six regions were tested for SARS-CoV-2 total antibodies (IgG/IgM) using the WANTAI ELISA kit and Lassa virus IgG using ReLASV Pan-Lassa-NP-IgG ELISA.

resultsSARS-CoV-2 antibody prevalence was 64.29% (n = 279) and Lassa virus IgG prevalence was 20.28% (n = 88). Of the cohort of subjects who were seropositive for SARS-CoV-2, 20.79% were also seropositive for LASV IgG. Multivariate analysis revealed household size as a strong risk factor of dual exposure. Individuals from medium-sized households (4-6 persons) (aOR = 8.78, 95% CI: 1.18-65.56, p = 0.034) and large households (≥ 7 persons) (aOR = 12.90, 95% CI: 1.99-83.40, p = 0.007) had significantly increased odds of dual seropositivity compared to small households. Regional variations were observed, with Greater Accra showing significantly lower odds of dual seropositivity (aOR = 0.13, 95% CI: 0.03-0.51, p = 0.004) compared to Ashanti Region.

conclusionThis study provides serological evidence of SARS-CoV-2 and Lassa virus concurrent exposure in Ghana during the COVID-19 pandemic. This finding suggests large household size as a key driver of dual viral exposure and calls for integrated surveillance systems and targeted interventions in large household settings to reduce concurrent transmission of viruses with pandemic potential.

Indexed as

CoinfectionCOVID-19Lassa FeverLassa virusSARS-CoV-2AdolescentAdultAgedAntibodies, ViralChildChild, PreschoolCross-Sectional StudiesFemaleGhanaHumansImmunoglobulin GAntibodies, ViralImmunoglobulin GImmunoglobulin MDual exposureHousehold transmissionLassa virusSARS-CoV-2Seroprevalence

Identifiers

PMID41421982
PMCPMC12831435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.